Stemline Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells

Investor FAQs

Investor FAQs

Show all

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated clinical activity including durable complete responses (CRs) and an overall survival (OS) benefit versus historical controls in Phase I/II studies.
Stemline is traded on the NASDAQ capital market under the symbol "STML".
Stemline's initial public offering occurred on January 28, 2013.
Stemline is incorporated in Delaware.
Stemline's corporate headquarters are located at 750 Lexington Ave, 11th Floor, New York, NY 10022. The main telephone number is (646) 502-2310 (646) 502-2310 call
Stemline does not pay a dividend at this time.
Computershare Trust Company, N.A.
P.O. Box 43078
Providence, RI 02940
www.computershare.com
1-800-962-4284 call(from the US, Canada, Puerto Rico)
1-781-575-3120 call(non-US)
December 31


Copyright 2017 - Stemline Therapeutics, Inc. All rights reserved